Market Overview

Merck Pleased with FDA Advisory Committee Recommendation for Approval of Vorapaxar


Merck (NYSE: MRK),
known as MSD outside the United States and Canada, today said it was
pleased with the U.S. Food and Drug Administration (FDA)'s
Cardiovascular and Renal Drugs Advisory Committee's recommendation for
approval of vorapaxar. Vorapaxar is the company's investigational
antiplatelet medicine for the reduction of atherothrombotic events, when
added to standard of care, in patients with a history of heart attack
and no history of stroke or transient ischemic attack.

“There are approximately 7.6 million Americans who have survived a heart
attack. Each year, about 190,000 of them have a recurrent heart attack,
so there remains a need for additional treatment options,” said Dr.
Daniel Bloomfield, vice president, Cardiovascular Diseases, Merck

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (MRK)

View Comments and Join the Discussion!